Buckley, E. | Search bioRxiv

bioRxiv2026

Smartphone Placement Recognition during Walking: Performance Determinants and Real-World Generalizability

The opportunity to collect movement data from smartphones for prolonged periods has opened new perspectives in the field of clinical movement analysis. However, when monitoring peoples mobility in free-living conditions, smartphone placement can influence the validity of the extracted digital mobility outcome. This study aimed to develop and validate an automatic smartphone placement recognition classifier and to investigate potential critical factors that can influence performance. The classifier was trained on data from 15 healthy participants using inertial signals collected from smartphones placed at six body placements during free-living walking and externally validated on over 3,000 individuals from external datasets, including blind participants and patients with cardiovascular or Parkinsons disease. A decision-tree ensemble model was developed using feature subsets of increasing dimensionality, with the optimal subset comprising 50 features. Classification accuracy increased consistently when front and back pocket placements were aggregated (81.1%) and further improved when coat pocket was also included in the pocket class (88.5%), underscoring the challenge of distinguishing between fine-grained pocket placements. The best-recognized placements across the external datasets were lower back (precision: 100%, recall: 72.5%), hand (precision: 94.2%, recall: 94.5%), and the aggregated pocket class (precision: 86.7%, recall: 90.2%). Recognition accuracy changed across cohorts (0.73 - 0.85), activities (0.63 - 0.94) and speed (0.79 - 0.87), however it stayed consistent across various technological and environmental factors. Overall, this study demonstrates the feasibility of robust placement recognition in walking and underscores the importance of accounting for key influencing factors when designing frameworks intended for deployment in heterogeneous real-world or clinical contexts. HighlightsO_LIMachine learning accurately identifies smartphone placement during real-world gait C_LIO_LISix on-body placements recognized, including pockets, hand, bag, and lower-back C_LIO_LIFree-living data used for training, ensuring robust performance across conditions C_LIO_LIFeature selection and hyperparameter tuning optimize classification accuracy C_LIO_LIExternal validation confirms generalizability across >3,000 healthy and diseased adults C_LI

bioengineering↗

bioRxiv2025

Inhibition of p38 MAPK after repetitive mild TBI ameliorates immune signaling and behavioral deficits

BackgroundMild traumatic brain injury (mTBI) can cause long-term functional impairments, and repetitive mTBIs within a window of vulnerability can exacerbate these consequences compared to a single mTBI. However, current interventions for mTBI focus on alleviating symptoms, rather than targeting underlying mechanisms. Following the initial mechanical impact, increasing evidence suggests that the brain undergoes an inflammatory cascade consisting of pro-inflammatory intracellular signaling pathways and production of cytokines, ultimately leading to chronic neuroinflammation and persistent neurological deficits. Prior work in severe traumatic brain injury has shown that the p38 MAPK signaling pathway is a key regulator of microglial activation, proinflammatory cytokines, and synaptic dysfunction, but its role in the context of mTBI remains unclear. As such, this study aimed to determine if inhibition of p38 MAPK would attenuate the inflammatory response and longer-term functional deficits following a weight-drop mouse model of repetitive mTBI. MethodsC57BL/6J male and female mice were injected with a small molecule p38 MAPK inhibitor (SB239063) after each of 5 once-daily weight-drop closed head injuries (CHIs) or sham injuries. Functional outcome was assessed at 4-weeks post injury. Protein and transcriptional alterations associated with the immune response, synaptic function, microglial phenotype, and functional outcomes were assessed at both 4-hours and 4-weeks after the final CHI. ResultsIn females, acute inhibition of p38 MAPK attenuated i) cytokine expression and microglial reactivity at 4-hours post injury and ii) antidepressive-like behavior and synaptic loss at 4-weeks post injury. In males, p38 MAPK inhibition also attenuated microglial reactivity and up-regulation of specific cytokines, although changes in functional outcomes did not reach significance. Interestingly, bulk RNAseq analysis in both sexes showed that acute p38 MAPK inhibition both normalized the effects of injury and upregulated protective genes and pathways associated with recovery and maintenance of brain homeostasis. Together, these findings suggest a role for p38 MAPK in driving the acute and longer-term consequences post repetitive mTBI in a sex-dependent manner, and they suggest therapeutic potential of p38 MAPK inhibition. To our knowledge, this work is the first to investigate the effects of small molecule inhibitor SB239063 as a potential therapeutic treatment administrated following rmTBI.

molecular biology↗